Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Update on the therapeutic benefits of adalimumab in Crohn's disease

Feb. 7, 2005

ANA-975 enters phase I study

Feb. 7, 2005

Pegasys receives European approval for HIV-HCV coinfected patients

Feb. 4, 2005

Protective effects of green tea polyphenols against acetaminophen-induced liver damage

Feb. 2, 2005

Gabexate mesilate tested for therapeutic potential in gut hypoperfusion

Feb. 2, 2005

5HT-7 receptor modulators and their use in IBS claimed by Ajinomoto

Feb. 1, 2005

Rigel claims agents for hepatitis C infection

Feb. 1, 2005

Sho-saiko-to selectively inhibits CD8+ cells

Feb. 1, 2005

XOS supplementation reported to improve the gastrointestinal microflora of obese patients

Feb. 1, 2005

iNOS inhibitor, GW-274150, is protective in experimental colitis

Jan. 31, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...